Department of Colorectal Cancer, Key Laboratory of Cancer Prevention and Therapy, and National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Department of Pathology, Key Laboratory of Cancer Prevention and Therapy, and National Clinical Research Center of Cancer, Cancer Hospital of Tianjin Medical University, Tianjin, China.
Colorectal Dis. 2019 Apr;21(4):427-431. doi: 10.1111/codi.14538. Epub 2019 Jan 12.
The aim was to examine the effect of activated carbon nanoparticles (ACNs) on lymph node retrieval in colorectal cancer (CRC) patients.
This prospective randomized study of 80 subjects was performed between March 2016 and December 2016. Eighty patients with CRC were randomly divided into two groups, the ACN group and a control group. The patients in the ACN group were subjected to 1 ml of ACN injection in the subserosa around the tumour before colectomy and D3 lymphadenectomy. The patients in the control group received the same procedure without the injection of ACNs. After surgery, lymph nodes were isolated, and the greatest dimensions were measured by the same pathologist.
The average number of lymph nodes harvested from each patient was markedly more in the ACN group (31.3 ± 8.1) than in the control group (21.9 ± 5.3; P < 0.001), and the average number of lymph nodes less than 5 mm in greatest dimension was significantly more in the ACN group (11.9 ± 4.9) than in the control group (4.1 ± 2.4; P < 0.001). The ACN group (15/40) had a higher rate of Stage III patients compared to the control group (6/39; P = 0.026). Besides, the greatest dimension of 32.8% metastatic lymph nodes was less than 5 mm.
There is significant upstaging following the use of ACNs, which could find more involved nodes. Therefore, ACNs can be used as a tracer to harvest more lymph nodes in CRC patients, with improvement in the accuracy of pathological staging.
研究活性炭纳米颗粒(ACN)对结直肠癌(CRC)患者淋巴结检出的影响。
这是一项于 2016 年 3 月至 2016 年 12 月进行的 80 例患者前瞻性随机研究。80 例 CRC 患者随机分为 ACN 组和对照组。ACN 组患者在结肠切除术和 D3 淋巴结清扫术前行肿瘤周围浆膜下注射 1ml ACN。对照组患者接受相同的程序,但不注射 ACN。手术后,由同一位病理学家分离淋巴结并测量最大直径。
ACN 组每位患者平均采集的淋巴结数量明显多于对照组(31.3±8.1 vs. 21.9±5.3;P<0.001),最大直径小于 5mm 的淋巴结数量也明显多于对照组(11.9±4.9 vs. 4.1±2.4;P<0.001)。ACN 组(15/40)有更高比例的 III 期患者,而对照组为 6/39(P=0.026)。此外,32.8%转移淋巴结的最大直径小于 5mm。
使用 ACN 后分期显著升高,可能发现更多受累淋巴结。因此,ACN 可作为 CRC 患者采集更多淋巴结的示踪剂,提高病理分期的准确性。